<DOC>
	<DOCNO>NCT01363011</DOCNO>
	<brief_summary>This study characterize effect cobicistat-based regimens parameter renal function participant HIV infection mild moderate renal impairment , assess safety tolerability regimens order generate appropriate dosing recommendation .</brief_summary>
	<brief_title>Cobicistat-containing Highly Active Antiretroviral Regimens HIV-1 Infected Patients With Mild Moderate Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Cobicistat</mesh_term>
	<criteria>Cohort 1 ( treatmentnaive ) Plasma HIV1 RNA level ≥ 1,000 copies/mL screen Screening genotype report must show sensitivity FTC TDF No prior use approved investigational antiretroviral drug length time Cohort 2 ( treatmentexperienced , pharmacoenhancer switch ) Subjects must receive ATV 300 mg/ritonavir ( RTV ) 100 mg plus 2 NRTIs OR DRV 800 mg/RTV 100 mg plus 2 NRTIs least 6 month prior screen Plasma HIV1 RNA concentration undetectable level 6 month precede screen visit HIV1 RNA &lt; 50 copies/mL screen Subjects experience intolerance RTV ( determine investigator ) Both group The ability understand sign write informed consent form Normal ECG Mild moderate renal function Stable renal function Hepatic transaminase ( AST ALT ) ≤ 5 x upper limit normal range ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin ( subject document Gilbert 's Syndrome hyperbilirubinemia due atazanavir therapy may total bilirubin 5 x ULN ) Adequate hematologic function Serum amylase ≤ 5 x ULN Males females childbearing potential must agree utilize highly effective contraception method screen throughout duration study treatment 30 day follow last dose study drug Age ≥ 18 year New AIDSdefining condition diagnose within 30 day prior screen Receiving drug treatment hepatitis C , anticipate receive treatment hepatitis C Subjects experience decompensated cirrhosis Females breastfeed Positive serum pregnancy test ( female childbearing potential ) Implanted defibrillator pacemaker Current alcohol substance use judge investigator potentially interfere subject study compliance History malignancy within past 5 year ongoing malignancy cutaneous Kaposi 's sarcoma , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior baseline Receiving ongoing therapy medication contraindicate use elvitegravir ( EVG ) , COBI , FTC , TDF , ATV , DRV ; subject know allergy excipients E/C/F/TDF STR , COBI tablet , ATV capsule DRV tablet contraindicate 2 NRTIs part PI/co regimen Participation clinical trial without prior approval Any clinical condition prior therapy would make subject unsuitable study unable comply dosing requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Naive</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>